Mounjaro, or tirzepatide if you want to be more specific, has been called the most successful weight-loss drug ever introduced to the market, and by the majority of quantifiable criteria, that assertion is supported. Over the course of about 72 weeks, people on the highest maintenance dose typically lose 22 to 25 percent of their body weight. Those figures feel almost miraculous to someone who has fought the same 30 or 40 kilograms for years. The issue arises later. And it arrives quickly.
People regain their weight when they stop taking Mounjaro. This is neither a marginal finding nor a negative interpretation of a small number of outlier studies. It is the consistent result found in real-world data, meta-analyses, and clinical trials.
People who stop taking weight-management drugs like tirzepatide gain weight at an average rate of about 0.4 kilograms per month; for those on newer, more effective drugs like Mounjaro, that rate is closer to 0.8 kilograms per month, according to a systematic review published in the BMJ in early 2026, which drew on 37 studies and over 9,000 participants. At that rate, the majority of patients reach their initial weight within 18 months of ceasing treatment.
The SURMOUNT-4 clinical trial statistics are especially useful. After receiving weekly Mounjaro injections for 36 weeks, participants in that study lost about 21% of their body weight. After that, half of them were discreetly switched to a placebo, and the other half continued taking the actual drug.
After a year, people taking the placebo had gained 14% more weight, or about 11 kg on average, while people continuing to take Mounjaro had lost an additional 5.5%. There was a noticeable difference. It implied something crucial: the medication is not a course of treatment with a natural endpoint for the majority of patients. It is more akin to a chronic condition management tool.
It’s necessary to take a quick look back at how Mounjaro functions in order to understand why this occurs. The medication imitates GLP-1 and GIP, two hormones that control hunger, slow the passage of food through the digestive system, and alert the brain when a person is full. Hunger subsides when someone is on Mounjaro. Food noise, which many overweight people describe as a persistent, low-level obsession with eating, softens or completely vanishes.
Digestion becomes slower. For longer, meals feel more fulfilling. All of that is reversed when the medication is stopped. Digestion picks up speed again, the hormonal signals return to their baseline, and appetite returns—sometimes even more strongly than before, according to reports. Mounjaro does not appear to permanently reset appetite, according to clinical research. For as long as it is taken, it effectively suppresses it.
Additionally, there is a more subdued aspect of cardiometabolic health. According to a late 2025 JAMA Internal Medicine study that examined SURMOUNT-4 trial participants, approximately 82% of those who stopped taking Mounjaro gained back at least 25% of the weight they had previously lost.
The cardiovascular risk indicators also increased as the weight returned: blood pressure, cholesterol, and waist circumference all slightly increased. Without the medication, the improvements it had brought about would not have lasted. According to the British Heart Foundation’s evaluation of those results, individuals may need to keep taking these medications in order to preserve the health advantages they received. That is an important finding that has practical ramifications for healthcare systems that are currently debating how to prioritize and finance these treatments.
All of this does not imply that stopping Mounjaro is a catastrophe or that everyone who leaves it will return to their starting point. Some people manage to sustain significant weight loss, especially those who have made use of the treatment period to establish enduring eating and exercise habits. Even though the medication suppresses hunger, it can make the initial months of behavior change much easier.
It is actually easier to establish new routines when cravings are suppressed than when hunger is constant. The problem is that those habits must be strong enough to endure the removal of the hormonal scaffolding. For many, they are not—not due to any personal shortcomings, but rather because obesity is a long-term, physiologically based illness, and the body has a strong biological inclination to defend its prior weight.
After stopping Mounjaro, the most often suggested strategies are protein intake, regular physical activity, consistent meal timing, and foods high in fiber. These recommendations are reasonable. Every meal should contain lean protein to help prevent hunger signals from coming back. Oats, beans, and vegetables contain soluble fiber, which slightly slows digestion and increases fullness.
The kind of intense hunger that results in big, impulsive meals can be avoided by eating roughly every three to four hours. Beyond its immediate metabolic effects, exercise aids in maintaining muscle mass during weight loss and promotes blood sugar control once the medication’s effect on glucose has subsided. These are practical instruments. Additionally, they are insufficient for many individuals on their own. For this reason, clinical researchers and obesity specialists are increasingly framing Mounjaro as a long-term intervention rather than a limited prescription, much like statins or blood pressure medications are used.
One idea that is becoming popular is the maintenance dose, which is a lower continuous dosage of Mounjaro taken to maintain weight loss that has already been attained rather than to lose more. It’s not an ideal solution. For many people, especially those who obtain the medication privately, cost continues to be a major obstacle.
The majority of people in the UK who pay for weight loss injections out of pocket spend hundreds of pounds each month, and the NHS’s eligibility requirements are still quite strict. A cautious, gradual dose reduction, as opposed to a sudden stop, seems to somewhat mitigate the rebound for those who truly cannot continue, but it does not completely eradicate it.
It is important to note what the Oxford researchers identified as possibly the central conflict in this case when they presented their findings at the European Congress on Obesity in the middle of 2025. Restrictive dieters who lose weight typically gain it back, albeit much more slowly. Over a period of five years or longer, the average diet dropout regains weight. In less than two years, people who stop taking GLP-1 medications like Mounjaro regain it.
One possible explanation is that, despite how taxing dieting is, it may eventually develop behavioral strategies that provide some residual protection, such as conscious restraint, food awareness, and portion control. Mounjaro eliminates the need for that deliberate effort, which contributes to its effectiveness. However, it might also imply that there is less residual protection when the medication is removed.
This presents a really challenging question for healthcare policy. What does Mounjaro’s long-term value mean if the benefits essentially vanish when the drug is stopped and if about half of patients stop taking it within the first year?
Does the NHS provide perpetual funding for individuals in need? Does it provide stronger behavioral and psychological support to help people stay on course when they do stray? To be honest, no one has figured this out completely yet, and more research is still required. It is evident that treating Mounjaro as a short-term intervention with a predetermined outcome—take it, lose the weight, stop, move on—is a strategy that does not align with the data.
The less dramatic point is probably the most helpful one for anyone navigating this personally: stopping Mounjaro does not imply failure is inevitable. Although weight gain is common—possibly the default—it is neither guaranteed nor irreversible.
Those who view the treatment period as an investment in real habit change rather than merely as a quick way to reach a particular score on the scale are the most likely to sustain some of their progress. Because of this framing, both patients and prescribers must be truthful about what this medication can and cannot accomplish on its own.
